India, March 12 -- Mumbai-based Glenmark Pharmaceuticals, a research-led, global pharmaceutical company, has launched Empagliflozin, a widely recognized SGLT2 inhibitor, in India.

The drug has been introduced under the brand name Glempa (Empagliflozin 10/25 mg), along with its fixed-dose combinations (FDCs)-Glempa-L (Empagliflozin 10/25 mg + Linagliptin 5 mg) and Glempa-M (Empagliflozin 12.5 mg + Metformin 500/1000 mg).

These medications are designed to improve glycemic control in adults with T2DM while also reducing cardiovascular outcomes in T2DM patients with CV risk.

Empagliflozin is a globally established treatment for HF,T2DMand T2DM with established cardiovascular disease (CVD), offering multiple benefits like cardiovascular and...